Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

被引:131
|
作者
Wimo, A [1 ]
Winblad, B
Stoffler, A
Wirth, Y
Möbius, HJ
机构
[1] Karolinska Inst, Neurotec, Sector Hlth Econ, Div Geriatr Epidemiol, Huddinge, Sweden
[2] Merz Pharmaceut GmbH, Frankfurt, Germany
关键词
D O I
10.2165/00019053-200321050-00004
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Alzheimer's disease (AD) is a devastating illness that causes enormous emotional stress to affected families and is associated with substantial medical and nonmedical costs. Objective: To determine the effects of 28 weeks of memantine treatment for patients with AD on resource utilisation and costs. Study design and methods: Multicentre, prospective, double-blind, randomised, placebo-controlled clinical trial performed in the US. The Wilcoxon-Mann-Whitney test was used to examine the resource utilisation variables and logistic regression models were used for multivariate resource utilisation analyses. Analysis of covariance (ANCOVA) models (log and non-log) were computed to examine costs from a societal perspective. All costs were calculated in 1999 US dollars. Study population: Outpatients with moderate to severe AD. Overall, 252 patients received randomised treatment, and 166 patients (placebo n = 76, memantine n = 90) formed the treated-per-protocol (TPP) subset for the health economic analyses, on which the main cost analysis was based. Main outcome measure: Resource Utilisation in Dementia (RUD) scale, measuring patient and caregiver resource utilisation, and various sources for cost calculations. Results: Controlling for baseline differences between the groups, significantly less caregiver time was needed for patients receiving memantine than for those receiving placebo (difference 51.5 hours per month; 95% CI -95.27, -7.17; p = 0.02). Analysis of residential status also favoured memantine: time to institutionalisation (p = 0.052) and institutionalisation at week 28 (p = 0.04 with the chi-square test). Total costs from a societal perspective were lower in the memantine group (difference $US1089.74/month [non-overlapping 95% Cl for treatment difference -1954.90, -224:58]; p = 0.01). The main differences between the groups were total caregiver costs ($US-823.77/month; p = 0.03) and direct nonmedical costs ($US-430.84/month; p = 0.07) favouring memantine treatment. Patient direct medical costs were higher in the memantine group (p < 0.01), mainly due to the cost of memantine. Conclusion: Resource utilisation and total health costs were lower in the memantine group than the placebo group. The results suggest that memantine treatment of patients with moderate to severe AD is cost saving from a societal perspective.
引用
收藏
页码:327 / 340
页数:14
相关论文
共 50 条
  • [1] Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer’s Disease
    Anders Wimo
    Bengt Winblad
    Albrecht Stöffler
    Yvonne Wirth
    Hans-Jörg Möbius
    [J]. PharmacoEconomics, 2003, 21 : 327 - 340
  • [2] Memantine therapy in patients with moderate to severe Alzheimer's disease
    Ochudlo, S
    Targosz, M
    Liberska, A
    Opala, G
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 235 - 235
  • [3] Memantine in moderate to severe Alzheimer’s disease
    Andrew Kertesz
    [J]. Current Neurology and Neuroscience Reports, 2003, 3 (6) : 485 - 486
  • [4] Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
    Hoogveldt, Bart
    Rive, Benoit
    Severens, Johan
    Maman, Khaled
    Guilhaume, Chantal
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2011, 7 : 313 - 317
  • [5] Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    Rive, B.
    Aarsland, D.
    Grishchenko, M.
    Cochran, J.
    Lamure, M.
    Toumi, M.
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 27 (06) : 573 - 582
  • [6] Memantine in moderate to severe Alzheimer's disease:: An analysis of individual response
    Ferris, S. H.
    Stoeffler, A.
    Wirth, Y.
    Reisberg, B.
    Moebius, H. J.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 38 - 38
  • [7] Efficacy of memantine in moderate to severe Alzheimer's disease
    Wilkinson, D.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 318 - 318
  • [8] Memantine in moderate-to-severe Alzheimer's disease
    Reisberg, B
    Doody, R
    Stoffler, A
    Schmitt, F
    Ferris, S
    Mobius, HJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (14): : 1333 - 1341
  • [9] Memantine (Namenda) for moderate to severe Alzheimer's disease
    Ables, AZ
    [J]. AMERICAN FAMILY PHYSICIAN, 2004, 69 (06) : 1491 - 1492
  • [10] Memantine in moderate-to-severe Alzheimer's disease
    Bleich, S
    Wiltfang, J
    Kornhuber, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (06): : 609 - 610